ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 37

β2-Glycoprotein I Binds to Necroptotic Cells and Serves As a Target for SLE Autoantibodies

David Salem1, Rebecca Subang1, Maziar Divangahi1, Christian Pineau2, Sasha Bernatsky3, Jerrold S. Levine4 and Joyce Rauch5, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 3Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 4Section of Nephrology, Department of Medicine, University of Illinois at Chicago and Jesse Brown Veterans Affairs Medical Center, Chicago, IL, 5Division of Rheumatology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Antiphospholipid antibodies, Apoptosis, autoantibodies, autoantigens and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: B Cell Biology and Targets in Autoimmune Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: β2-glycoprotein I (β2GPI), a phospholipid-binding protein, binds to apoptotic cells and serves as an antigenic target for autoantibodies from patients with systemic lupus erythematosus (SLE). Here, we determine whether this paradigm can be extended to necroptotic cells. Like apoptotic cells, necroptotic cells express phosphatidylserine on their surface and provide a “scaffold” of cellular self-antigens. We hypothesized that β2GPI should bind to necroptotic cells and serve as a target for anti-β2GPI autoantibodies from patients with SLE.

Methods: We established conditions for inducing necroptotic or apoptotic cell death in murine L929 fibroblast cells. L929 cells treated with vehicle served as the viable cell control. Cells were incubated with human β2GPI and murine monoclonal anti-β2GPI IgG antibody (or isotype control), and bound antibody detected with fluorescently conjugated anti-murine IgG. Similarly, binding of anti-β2GPI autoantibodies from human sera (or IgG isolated from these sera) was detected using fluorescently conjugated anti-human IgG. Human sera were from healthy controls and patients who satisfied the ACR classification criteria for SLE. Antibody binding was analyzed by flow cytometry and confocal microscopy.

Results: Using murine monoclonal anti-β2GPI antibody, we demonstrate that β2GPI binds to necroptotic cells in a similar manner as to apoptotic cells, but not to viable cells. Cells treated with an irrelevant antigen (serum albumin) or isotype control showed little or no antibody binding. Confocal microscopy confirmed monoclonal anti-β2GPI antibody staining of the cell surface of both necroptotic and apoptotic cells. SLE sera positive for anti-β2GPI autoantibodies bound to necroptotic cells and apoptotic cells. In contrast, sera negative for anti-β2GPI autoantibodies behaved similarly to healthy control sera, and showed little or no binding to necroptotic or apoptotic cells. Binding of purified IgG from the sera replicated the findings observed with sera.

Conclusion: Our data demonstrate that β2GPI binds to necroptotic cells and can serve as a target for SLE autoantibodies recognizing β2GPI. Based on these findings, we propose that the paradigm of apoptotic cells serving as a “cellular scaffold” of self-antigens in SLE may be extended to necroptotic cells.


Disclosure: D. Salem, None; R. Subang, None; M. Divangahi, None; C. Pineau, None; S. Bernatsky, None; J. S. Levine, None; J. Rauch, None.

To cite this abstract in AMA style:

Salem D, Subang R, Divangahi M, Pineau C, Bernatsky S, Levine JS, Rauch J. β2-Glycoprotein I Binds to Necroptotic Cells and Serves As a Target for SLE Autoantibodies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/%ce%b22-glycoprotein-i-binds-to-necroptotic-cells-and-serves-as-a-target-for-sle-autoantibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/%ce%b22-glycoprotein-i-binds-to-necroptotic-cells-and-serves-as-a-target-for-sle-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology